Company
(symbol)#

Date
filed

Date
comm.

Shares/
units
(M)

Price

Shares
out
(M)@

Lead, other
underwriters

Gross
(US$M)

Post-
offering
market
cap (M)%

INITIAL OFFERINGS TOTAL: $504.9M

Coherus Biosciences Inc. (Redwood City, Calif.; CHRS)1

9/25/14

11/6/14

6.8S

$13.50

32.6

J.P. Morgan (co-lead); Credit Suisse (co-lead); Cowen and Co.

$91.8

$440.1

Fibrogen Inc. (San Francisco; FGEN)2

10/1/14

11/14/14

9.3S

$18

57.84

Goldman, Sachs & Co. (co-lead); Citigroup (co-lead); Leerink Partners (co-lead); RBC Capital Markets; Stifel; William Blair

$167.4

$1,041.12

Molecular Partners AG (Schlieren, Switzerland; SWX:MOLN)3

11/10/14

11/10/14

4.307S

CHF22.40

19.28

N/A

$99.6

CHF431.9

Neoethics Inc. (formerly Lithera Inc.; San Diego; NEOT)4

11/12/14

11/12/14

4.6S

$14

N/A

Piper Jaffray (co-lead); Guggenheim Securities (co-lead); Needham & Co.

$65.1

N/A

Neuroderm Ltd. (Rehovot, Israel; NDRM)5

9/15/14

11/14/14

4.5S

$10

17

Jefferies (co-lead); Cowen and Co. (co-lead); Oppenheimer & Co.; Roth Capital Partners

$45

$170

Xenon Pharmaceuticals Inc. (Burnaby, British Columbia; XENE)6

9/10/14

11/5/14

4S

$9

13.6

Jefferies (co-lead); Wells Fargo Securities (co-lead); Cannacord Genuity

$36

$122.4


Number of IPOs in November: 6

Average value of November IPOs: $84.15M

Number of IPOs in 2014: 79

Total raised in IPOs in 2014: $5,896.09M

Average value of IPOs in 2014: $74.63M

FOLLOW-ON OFFERINGS TOTAL: $4,755.98M

Amicus Therapeutics Inc. (Cranbury, N.J.; FOLD)7

1/22/13

11/19/14

15.95S

$6.50

95.2

J.P. Morgan Securities (co-lead); Cowen and Co. (co-lead); Leerink Partners (co-lead); Janney Montgomery Scott

$103.5

$618.8

CTI Biopharma Corp. (Seattle; CTIC)8

8/29/12

11/7/14

0.035S

$1,000

N/A

Piper Jaffray (lead); Ladenburg, Thalmann; Roth Capital Partners; Janney Montgomery Scott

$35

N/A

Gilead Sciences Inc. (Foster City,, Calif.; GILD)9

11/14/14

11/14/14

Notes

N/A

N/A

BofA Merrill Lynch (co-lead); JP Morgan Securities (co-lead); Barclays Capital (co-lead); HSBC Securities (USA) (co-lead); Goldman, Sachs; MUFG; Mizuho Securities; RBC Capital Markets; SMBC Nikko; US Bancorp; Wells Fargo Securities; The Williams Capital Group

$4,000

N/A

Immune Pharmaceuticals Inc. (Herzlyia-Pituach, Israel; IMNP)10

10/28/14

11/20/14

3.91U

$2.50

22.56

National Securities Corp. (lead)

$9.78

$56.4

Lexicon Pharmaceuticals Inc. (The Woodlands, Texas; LXRX)11

9/12/14

11/19/14

49.8S

$1

N/A

J.P. Morgan Securities (co-lead); Goldman, Sachs (co-lead); Needham & Co.; Stifel, Nicolaus & Co.

$50

N/A

Mast Therapeutics Inc. (San Diego; MSTX)12

5/1/12

11/7/14

30.9U

$0.48

159.5

Cowen and Co. (lead); Canaccord Genuity (co-lead); Laidlaw & Co.; Merriman Capital

$21

$76.56

Medgenics Inc. (Philadelphia; MDGN)13

10/26/12

11/25/14

5.8S

$4.10

24.8

Piper Jaffray (lead); JMP Securities

$24.2

$101.68

Receptos Inc. (San Diego; RCPT)14

7/16/14

11/19/14

4.1S

$100

31.5

Credit Suisse Securities (USA) (co-lead); Leerink Partners (co-lead); Evercore Group; BMO Capital Markets; Wedbush Pacgrow Life Sciences; Nomura Securities International

$414

$3,150

Rockwell Medical Inc. (Wixom, Mich.; RMTI)15

6/13/12

11/17/14

6.5S

$9

47.5

BofA Merrill Lynch (co-lead); Stifel (co-lead); Summer Street, Craig-Hallum, Chardan Capital Markets; Lifesci Capital

$59

$427.5

Trevena Inc. (King of Prussia, Pa.; TRVN)16

11/20/14

11/20/14

N/A

N/A

N/A

Barclays (co-lead); Cowen and Co. (co-lead); Jefferies & Co. (co-lead); JMP Securities; Needham & Co.

$40

N/A


Number of follow-on offerings in November: 10

Average value of November follow-ons: $475.6M

Number of follow-on offerings in 2014: 121

Total raised in follow-ons in 2014: $15,864.94M

Average value of follow-ons in 2014: $131.12M

Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics.

1 Includes Coherus' overallotment option: 507,402 shares.

2 Includes Fibrogen's overallotment option: 1.2M shares. Fibrogen raised an additional $20M through a concurrent private placement with Astrazeneca plc.

3 Molecular's overallotment option: 660,000 shares.

4 Neoethics' overallotment option: 697,500 shares.

5 Neuroderm's overallotment option: 675,000 shares.

6 Xenon's overallotment option: 600,000 shares. Concurrently, the company is selling 495,000 shares in a private placement.

7 Includes Amicus' overallotment option: 2.08M shares.

8 CTI offered 35,000 convertible preferred shares at $1,000 each. They can be converted at $2 per share into 17.5M common shares.

9 Gilead priced senior unsecured notes worth $4B in a registered public offering consisting of three tranches: $500M of 2.35% senior notes maturing in February 2020; $1.75B of 3.5% senior notes maturing in February 2025; and $1.75B of 4.5% senior notes maturing in February 2045.

10 Includes Immune's overallotment option: 460,000 units. Each unit consists of one share and one warrant to purchase 0.25 of a share.

11 Lexicon's overallotment option: 7.5M shares.

12 Mast's units each consist of one share of common stock and one-half of a warrant.

13 Includes Medgenics' overallotment option: 768,750 shares.

14 Includes Receptos' overallotment option: 540,000 shares.

15 Rockwell's overallotment option: 975,000 shares.

16 Trevena's overallotment option $6M worth of shares.